Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing